FINWIRES · TerminalLIVE
FINWIRES
$MRK

$MRK

63 stories mentioning MRKUpdated just now

Every FINWIRES story that references MRK, newest first.

Wire

Lupin Launches Sugammadex Injection in US Following FDA Approval

Lupin said Thursday it has launched Sugammadex Injection in the US following approval from the US Food and Drug Administration.The firm said the drug, a bioequivalent to Merck's (MRK) Bridion Injection, is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.Price: $129.29, Change: $-1.08, Percent Change: -0.82%

$MRK
Wire

Merck Keeps Quarterly Dividend at $0.85 per Share; Payable Oct. 7 to Holders of Record on Sept. 15

Merck Keeps Quarterly Dividend at $0.85 per Share; Payable Oct. 7 to Holders of Record on Sept. 15

$MRK
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Merck (MRK) shares gained 3% after it said Thursday that the Food and Drug Administration has approved Lipfendra 20 mg tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.UnitedHealth (UNH) shares rose 1.7% after it posted higher Q2 adjusted earnings and revenue and raised its 2026 adjusted EPS outlook.AtaiBeckley (ATAI) shares surged 32% after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion. Lilly was up 0.8%.Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported Q2 results above market estimates. Abbott shares jumped past 10%.

$ABT$ATAI$LLY$MRK$UNH
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Merck (MRK) shares gained 3.5% after it said Thursday that the Food and Drug Administration has approved Lipfendra 20 mg tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

$MRK
Wire

Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says

Merck (MRK) is approaching key pipeline catalysts with ISLEND and islatravir plus ulonivirine data that could drive its HIV franchise, RBC Capital Markets said in a note Thursday.The analysts said that while the April approval of Idvynso expanded Merck's commercial presence, bigger inflection points are expected later this month with the International AIDS conference and Merck's Aug. 3 investor update.At the conference, Merck will present detailed phase 3 ISLEND-1 and ISLEND-2 data along with phase 2b ISL/ULO results. Initial ISLEND results announced in June showed ISL/LEN met non-inferiority goals versus Biktarvy and standard-of-care antiretroviral therapy at week 48 in virologically suppressed patients, the analysts said.Importantly, no new safety concerns were reported, "an important signal on the CD4/lymphocyte front that had been the single most-watched variable for the islatravir program given its class history," the analysts said, adding that the upcoming data will help determine the drug's commercial potential and timing of a potential new drug application filing.RBC has an outperform rating and a $142 price target on Merck.Price: $127.85, Change: $+4.24, Percent Change: +3.43%

$MRK
Sectors

Sector Update: Healthcare Stocks Decline Premarket Wednesday

Healthcare stocks were declining premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) 0.1% lower.Elevance Health (ELV) shares were down more than 8% after the company reported lower Q2 adjusted earnings.Johnson & Johnson (JNJ) stock was down more than 2% even after the company posted higher fiscal Q2 adjusted earnings and reported sales, and raised its fiscal 2026 outlook.Merck (MRK) shares were up more than 2% after the company said its phase 3 trial of its therapy, Keytruda, met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer.

$ELV$IBB$JNJ$MRK$XLV
Asia Markets

Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were edging slightly higher pre-bell Wednesday as traders considered the latest inflation data amid the continuing tensions in the Middle East.Dow Jones Industrial Average futures were 0.1% higher, S&P 500 futures were up 0.2%, and Nasdaq futures were 0.5% higher.The US seasonally adjusted consumer price index, a measure of inflation, fell by 0.4% in June, compared with expectations for a 0.1% decrease in a survey compiled by Bloomberg and following a 0.5% increase in May, government data showed.In a post on X, US Central Command said it started another wave of attacks against Iran at 6 am ET, aiming to "further degrade military capabilities Iranian forces have used to attack commercial shipping in the Strait of Hormuz."President Donald Trump reiterated in a post on Truth Social that the US was reinstating a "full" blockade, "but only on Ships coming to and from Iranian ports, or carrying anything have to do with Iranian cargo." Trump also backtracked from a threat to impose a 20% levy on cargo shipped through the Strait of Hormuz, saying that the Gulf States would invest in the US instead.Traders also digested the latest round of earnings with ASML (ASML) reporting higher Q2 earnings and sales, and Johnson & Johnson (JNJ) posted an increase in Q2 adjusted earnings and sales.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 0.4% at $85.04 per barrel and US West Texas Intermediate crude 0.5% higher at $79.72 per barrel.The US Producer Price Index, released at 8:30 am ET, fell 0.3% in June following a 0.6% increase in May, compared with no change expected in a survey compiled by Bloomberg. The New York Federal Reserve's Empire State manufacturing index jumped to 15.6 in July from 5.7 in June, compared with expectations of a smaller increase to a reading of 9.2.Federal Reserve Chair Kevin Warsh will testify before the Senate Banking Committee at 10 am ET, following a similar presentation Tuesday before the House.Federal Reserve New York President John Williams, St. Louis President Alberto Musalem, and Governor Lisa Cook are slated to speak on Wednesday.In other world markets, Japan's Nikkei closed 1.5% higher, Hong Kong's Hang Seng ended 1.4% higher, and China's Shanghai Composite finished 0.3% lower. Meanwhile, the UK's FTSE 100 was flat, and Germany's DAX index was 0.6% lower in Europe's early afternoon session.In equities, ASML stock was up 3.2% after the company reported its Q2 financial results. Alibaba's (BABA) shares were 4.1% higher after a Bloomberg report cited a company spokesperson as saying that Apple (AAPL) would be integrating the Alibaba's Qwen AI into Chinese iPhones, iPads, and Mac operating systems. Merck (MRK) stock was up 2.3% after the company said the phase 3 trial of its therapy, Keytruda, met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer.On the losing side, Johnson & Johnson shares fell 2.1% after the company posted its Q2 financial results.

Dow JonesNasdaq CompositeS&P 500$AAPL$ASML$BABA$JNJ$MRK
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Economic Reports

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.4% in Wednesday's premarket activity, amid economic data releases.US stock futures were also higher, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures slipping 0.02%, and Nasdaq futures gaining 0.4% before the start of regular trading.Mortgage applications fell by 2.7% in the week ended July 10 as higher 30-year mortgage rates depressed new home applications, while refinancing activity improved, according to Mortgage Bankers Association data released Wednesday.The New York Federal Reserve's Empire State manufacturing index rose to 15.6 in July from 5.7 in June, compared with a smaller expected increase to a reading of 9.2 in a survey compiled by Bloomberg.US producer prices fell 0.3% in June, compared with expectations for no change, while core producer prices rose 0.2%, below forecasts for a 0.3% increase.Fed Chair Kevin Warsh begins his second day of testimony at 10:00 am ET.Weekly crude oil stocks data are set for release at 10:30 am ET, followed by an appearance byNew York Fed President John Williams and Fed Governor Lisa Cook are slated to speak on Wednesday.The Fed's Beige Book report will be released at 2:00 pm ET.In premarket action, bitcoin was up by 0.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.1% higher, Ether ETF (EETH) advanced 0.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated 0.01%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, the Vanguard Industrials Index Fund (VIS) rose 1%, while the iShares US Industrials ETF (IYJ) was inactive.Pentair (PNR) stock fell more than 21% before the opening bell after the water treatment company reported preliminary Q2 results below market estimates and lowered its full-year outlook amid headwinds related to its pool segment.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.1% lower.BlackRock (BLK) shares traded up more than 4% in early hours activity after Bloomberg reported the company is in discussions over providing about $45 million in private credit to Indian e-commerce platform Udaan as part of a proposed $160 million funding package.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 0.6%, and the iShares US Technology ETF (IYW) was 0.2% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.5%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained 1.1%, while the iShares Semiconductor ETF (SOXX) rose by 1.4%.ASML (ASML) shares were up more than 3% in premarket activity after the company reported year-over-year growth in Q2 earnings and sales and raised revenue guidance for the full-year 2026.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) retreated 0.01%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat, and the iShares US Consumer Staples ETF (IYK) was up 1.2%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advanced 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Lucid (LCID) shares were down more than 2% pre-bell after dropping more than 16% in Tuesday's regular session following rumors of a potential bankruptcy filing that the company quashed.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) declined 0.6%, the Vanguard Health Care Index Fund (VHT) was down 0.3%, while the iShares US Healthcare ETF (IYH) slipped 0.3%. The iShares Biotechnology ETF (IBB) was up 0.2%.Merck (MRK) stock was up more than 1% premarket after the company said a phase 3 trial of its therapy, Keytruda, met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer.EnergyThe iShares US Energy ETF (IYE) was down 2.5%, while the State Street Energy Select Sector SPDR ETF (XLE) retreated by 0.1%.Oceaneering International (OII) stock was up nearly 1% before market open after the company and Kongsberg were selected by the US Department of War's Defense Innovation Unit to support the US Navy's vision for scalable uncrewed undersea platforms.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 0.6% to $79.82 per barrel on the New York Mercantile Exchange. Natural gas was down by 0.2% to $2.90 per 1 million British Thermal Units. The United States Oil Fund (USO) was up 0.1%, while the United States Natural Gas Fund (UNG) was 0.9% lower.Gold futures for July gained 0.8% to $4,035.90 an ounce on the Comex. Silver futures retreated by 1.4% to $58.28 an ounce. SPDR Gold Shares (GLD) decreased 0.4%, and the iShares Silver Trust (SLV) was 1.2% lower.

Dow JonesNasdaq CompositeS&P 500$ASML$BETH$BITO$BLK$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LCID$MRK$OII$PMR$PNR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug

Cosmos Health (COSM) said Monday it has entered into a distribution and promotion deal with Libytec Pharmaceutical for its type-2 diabetes medication DIABIT-IS X in Greece.The company said its Cana Laboratories unit will provide the supply, while Libytec will manage distribution, medical information and promotional activities across Greece.The five-year arrangement is projected to lift revenue and cash flow while positioning the business to introduce the product in additional European markets, the company added.The medicine, which contains the active substance sitagliptin, is a generic version of Merck's (MRK) Januvia, Cosmos Health said.Shares of the company were up 8.3% in Monday trading.Price: $0.32, Change: $+0.02, Percent Change: +8.27%

$COSM$MRK
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Wire

Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer

Merck's (MRK) pembrolizumab, alone or with berahyaluronidase alfa-pmph, each in combination with enfortumab vedotin-ejfv, won US Food and Drug Administration approval on Friday as neoadjuvant treatment before surgery followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer.The approval expands the regimen's previously authorized use from patients who were ineligible for cisplatin to all patients with muscle-invasive bladder cancer who are candidates for cystectomy.The approval was based on a late-stage trial showing statistically significant improvements in event-free survival and overall survival compared with neoadjuvant gemcitabine and cisplatin, the FDA said.Price: $124.05, Change: $-1.02, Percent Change: -0.82%

$MRK
Wire

Merck Likely to Post Inline Q2 Revenue, RBC Says

Merck's (MRK) Q2 revenue is likely to be in line with consensus estimates as its Keytruda immunotherapy and Gardasil HPV vaccine sales are tracking at expected levels, RBC Capital Markets said in a Wednesday research report.The brokerage said its revenue estimate for fiscal 2026 is higher than the company's guidance, implying room for a potential upward revision. The company is due to report Q2 results on Aug. 4.Keytruda's US growth continues at a more moderate pace, as it nears peak penetration in key tumor types amid looming global pricing headwinds, while Gardasil growth should be stable from a year earlier excluding China, according to the note.The brokerage said it reiterated its outperform rating on the stock and price target of $142 per share.Price: $126.18, Change: $-2.68, Percent Change: -2.08%

$MRK
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 2.3%.The iShares Biotechnology ETF (IBB) climbed 2.1%.In corporate news, AbbVie (ABBV) and other healthcare stocks were rising after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare. According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference. AbbVie rose 3.8%, Johnson & Johnson (JNJ) was up 3.2%, Bristol-Myers Squibb (BMY) climbed 3.4%, and Merck (MRK) added 2.7%.Crinetics Pharmaceuticals (CRNX) shares jumped 9% after UBS started coverage of the stock with a buy rating and a price target of $55 per share.Ensign (ENSG) shares rose 1.4% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.DarioHealth (DRIO) shares jumped 5.9% after it said Thursday that a health insurer in the US extended its agreement with the company and expanded the scope by adding its AI-powered hypertension offering.

$ABBV$BMY$CRNX$DRIO$ENSG$JNJ$MRK
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.1%.The iShares Biotechnology ETF (IBB) advanced 1.6%.In corporate news, AbbVie (ABBV) and other healthcare stocks were rising after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare. According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference. AbbVie rose 3.2%, Johnson & Johnson (JNJ) was up 2.9%, Bristol-Myers Squibb (BMY) gained 2.4%, and Merck (MRK) added 2.2%.Ensign (ENSG) shares rose 1.7% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.Exelixis (EXEL) offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said. The firm raised its price target on Exelixis to $52 from $43 and reiterated its neutral rating. Exelixis shares added 1.8%.

$ABBV$BMY$ENSG$EXEL$JNJ$MRK
Wire

Sector Update: Healthcare

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.1%.The iShares Biotechnology ETF (IBB) advanced 1.5%.In corporate news, AbbVie (ABBV) and other healthcare stocks were rising after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare. According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference. AbbVie rose 3.4%, Johnson & Johnson (JNJ) was up 2.8%, Bristol-Myers Squibb (BMY) gained 2.6%, and Merck (MRK) added 2.2%.

$ABBV$BMY$JNJ$MRK
Wire

AbbVie, Other Healthcare Stocks Rise as Trump Administration Reportedly Targets Hospital Drug Markups

AbbVie (ABBV) and other healthcare stocks were rising in recent Thursday trading after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare.According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference.The move could save consumers about $1.1 billion next year, according to estimates obtained by The Associated Press.AbbVie rose 3.1%, Johnson & Johnson (JNJ) was up 2.5%, Bristol-Myers Squibb (BMY) gained 2.8%, and Merck & Co. (MRK) rose 2.1% in the session.The White House didn't immediately reply to' request for comment.Price: $259.00, Change: $+7.94, Percent Change: +3.16%

$ABBV$BMY$JNJ$MRK
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira shares rose 1%, and Zimmer fell past 6%.Unicycive Therapeutics (UNCY) shares tumbled 40% after it said Tuesday it has received a Complete Response Letter from the US Food and Drug Administration over its resubmitted new drug application for oxylanthanum carbonate for treating hyperphosphatemia in people with chronic kidney disease on dialysis.AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US House over whether clinical trials conducted in China may have contributed to the country's military capabilities, Reuters reported. AbbVie shares were down 1.3%, and Merck shed nearly 1%.Align Technology (ALGN) shares fell 3% after the European Commission said Tuesday it has opened an antitrust probe to determine whether the company has violated EU competition rules by tying its dental clear aligners to its intra-oral scanners in the European Economic Area.

$ABBV$ALGN$MRK$PCRX$UNCY$ZBH
Sectors

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) rose 0.6%.In corporate news, AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US House over whether clinical trials conducted in China may have contributed to the country's military capabilities, Reuters reported. AbbVie shares were down 0.6%, and Merck shed 0.7%.Align Technology (ALGN) shares fell 2.9% after the European Commission said Tuesday it has opened an antitrust probe to determine whether the company has violated EU competition rules by tying its dental clear aligners to its intra-oral scanners in the European Economic Area.PetMed Express (PETS) shares surged 10% after it said Tuesday it received an unsolicited, non-binding and conditional proposal from SilverCape Investments to buy the company for $3 per share in cash.

$ABBV$ALGN$MRK$PETS
Wire

Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says

Merck's (MRK) upcoming phase 3 OptiTrop-Lung06 readout could establish SAC-TMT as a chemotherapy replacement in lung cancer, potentially supporting upside to $5 billion peak sales forecast, BofA Securities said in a note Tuesday.The analysts said OTL-06 will test whether SAC-TMT can replace chemotherapy as the treatment backbone in PD-L1-negative non-small cell lung cancer, or NSCLC. Based on prior data, they expect clinically meaningful improvements in progression-free survival and overall survival, based on modeled assumptions."A positive result could support further global development, but competitor readouts could alter development strategy," they added.Key questions for investors remain whether SAC-TMT can outperform chemotherapy alone, whether combining with Keytruda is sufficient or if alternative combinations such as PD-1 x VEGF are superior, and what level of efficacy is needed for meaningful differentiation, the analysts said.The analysts said they continue to forecast $5 billion in SAC-TMT sales by 2035, based on clinically de-risked indications including EGFR-mutated lung cancer, PD-L1-high lung cancer, endometrial cancer, and breast cancer.BofA raised its price target on Merck to $141 from $130 while keeping its buy rating.Price: $127.21, Change: $-2.18, Percent Change: -1.68%

$MRK
Wire

Scotiabank Raises Merck Price Target to $155 From $136, Sector Outperform Rating Kept

Merck (MRK) has an average rating of overweight and mean price target of $132.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $129.13, Change: $+0.47, Percent Change: +0.37%

$MRK

Showing 1-20 of 63

Track with the FINWIRES app suite